GSK Completes Enrollment for Landmark COPD-CVD Study

GlaxoSmithKline and Theravance have completed enrollment of 16,000 patients for SUMMIT, a study to determine the impact of GSK's Breo Ellipta on all cause mortality amongst patients with moderate COPD and cardiovascular disease.